Data are due in the fourth quarter for Aldeyra, Aeglea and Radius, among other small developers.
Deciphera, Allakos and Uniqure are all set for important data disclosures.
The fourth quarter will see key immunotherapy data from Astrazeneca and Merck, while full details on Glaxo's anaemia pill, daprodustat, are expected.
Two new immuno-oncology mechanisms post encouraging data, giving a boost to small developers including Innate and Corvus.
Adagrasib looks better than Amgen’s Lumakras, which could explain why Mirati has been dragging its heels in lung cancer.
A few developers are still finding reasons to research novel pandemic treatments, though much of the ongoing work is focused on proven approaches.
Clinical data on Carrick’s samuraciclib and Syros’s SY-5609 show that this mechanism remains a work in progress.